SD Biosensor Inc (137310) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of SD Biosensor Inc KRW 18,210, price KRW 6,070, upside +200.0%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SD Biosensor Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa.
Show more
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disease diagnosis, drug resistance, and genetic testing. It also provides STANDARD i, an analyzer based on chemiluminescence immunoassay technology for detection of clinical biomarkers, including hormones, tumor markers, and infectious diseases; blood glucose meter products; and other products, such as transport medium, d-BLOCK incubator, G6PD analyzer, LipidoCare analyzer, MultiCare analyzer, and Pilot COVID-19 at-home test. The company exports its products. SD Biosensor, Inc. was founded in 1999 and is headquartered in Suwon-si, South Korea.
Stock analysis
SD Biosensor Inc (137310) currently trades at 6,070 KRW, while our model-based Fair Value estimate is 18,210 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 41,946 KRW per share, and 10 of the 10 models we run sit above the 6,070 KRW price.
Bear case: the Multiples group reads lowest at 6,407 KRW, and 0 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: 11,507 KRW (bear) to 27,631 KRW (bull), the price of 6,070 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
SD Biosensor Inc reported revenue of 711B KRW in FY2025 versus 2.9T KRW in FY2021, a compound −29.8%/yr. Reported net income was −512B KRW in FY2025.
Key figures
Market cap 726B KRW (≈ $508M) · P/S ratio 1.00 · Dividend yield 3.3% · Net margin −72.1% · Return on equity −18.0% · Return on assets (EBIT) 14.0% · Operating margin −7.0% · Revenue (TTM) 719B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 200%, 137310 screens cheaper than that median.
Fair Value models
Bear 11,507 KRWFair Value 18,210 KRWBull 27,631 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.1%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
43.8% (2020) → −11.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−21.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −22.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside+200% · Top 25%
Profitability
Return on assets−2% · Below median
Net margin (TTM)−65% · Bottom 25%
Operating margin (TTM)−7% · Below median
Growth and dividend
Revenue growth4% · Below median
Dividend yield (TTM)3.3% · Top 25%
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SD Biosensor Inc (137310) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 18,210 KRW versus a price of 6,070 KRW, about +200% upside (undervalued).
What is the fair value of 137310?
Our model-based fair value for SD Biosensor Inc is 18,210 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 6,070 KRW.
What is the quality score of 137310?
SD Biosensor Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SD Biosensor Inc (137310)?
Our model-based price target is the fair value of 18,210 KRW (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 11,507 KRW, optimistic scenario 27,631 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SD Biosensor Inc stock forecast for 2026?
Our models put fair value at 18,210 KRW, about +200% upside versus a price of 6,070 KRW (undervalued). Cautious scenario 11,507 KRW, optimistic scenario 27,631 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of SD Biosensor Inc (137310)?
SD Biosensor Inc reported trailing-twelve-month revenue of about 719B KRW (latest available figure, as of Sep 24, 2026).
Does SD Biosensor Inc pay a dividend?
SD Biosensor Inc currently shows a dividend yield of about 3.29% relative to its recent price (as of Sep 24, 2026).
What growth is priced into SD Biosensor Inc (137310)?
For today's price to be fair in a discounted-cash-flow model, SD Biosensor Inc would have to grow free cash flow by -21.1 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 137310 use?
Our models discount SD Biosensor Inc at 10.8 %: a base by market capitalisation (small), damped by beta 0.71, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SD Biosensor Inc that is -21.1 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has SD Biosensor Inc (137310) delivered so far?
Over the past 5 years revenue at SD Biosensor Inc grew -15.9 % a year. The price currently implies -21.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SD Biosensor Inc (137310) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into SD Biosensor Inc (-21.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SD Biosensor Inc (137310)?
The free-cash-flow yield on the price is 41.32 %: that much free cash flow SD Biosensor Inc produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SD Biosensor Inc (137310)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SD Biosensor Inc it is 18,210 KRW per share (as of Sep 24, 2026), against a price of 6,070 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is SD Biosensor Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 137310 trades below its calculated fair value: price 6,070 KRW, fair value 18,210 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 137310?
No. The price is what the market pays today (6,070 KRW); the fair value is what the company's own numbers justify (18,210 KRW). For SD Biosensor Inc the two are 12,140 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SD Biosensor Inc worth?
The market values SD Biosensor Inc at about 726B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 6,070 KRW; our models calculate a fair value of 18,210 KRW per share.
What do the bullish and bearish scenarios say about 137310?
Our models span a range for SD Biosensor Inc: cautious scenario 11,507 KRW, base 18,210 KRW, optimistic 27,631 KRW per share (as of Sep 24, 2026, price 6,070 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SD Biosensor Inc (137310)?
Balance-sheet figures for SD Biosensor Inc (as of Sep 24, 2026): return on equity −18.0%, debt of 0.15 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 137310 from its 52-week high?
SD Biosensor Inc trades at 6,070 KRW, about 42% below its 52-week high of 10,515 KRW and 4% above the low of 5,820 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 18,210 KRW is for.
Which stocks are comparable to SD Biosensor Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SD Biosensor Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 6,070 KRW, calculated fair value 18,210 KRW (+200%), Quality Score 51/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 137310 calculated?
We run SD Biosensor Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 18,210 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. SD Biosensor Inc currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SD Biosensor Inc (137310)?
The closing price on Sep 23, 2026 was 6,070 KRW. Our model-based fair value is 18,210 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SD Biosensor Inc right now?
The price is below even our cautious bear case (11,507 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (11,507 KRW to 27,631 KRW) leaves room in how you read the outcome.
Key figures of SD Biosensor Inc
How large is the market capitalisation of SD Biosensor Inc (137310)?
The market capitalisation of SD Biosensor Inc is 726B KRW (≈ $508M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SD Biosensor Inc (137310)?
The price-to-sales ratio of SD Biosensor Inc is 1.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of SD Biosensor Inc (137310)?
The dividend yield of SD Biosensor Inc is 3.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SD Biosensor Inc (137310)?
The net margin of SD Biosensor Inc is −72.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SD Biosensor Inc (137310)?
The return on equity (ROE) of SD Biosensor Inc is −18.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SD Biosensor Inc (137310)?
On an EBIT basis the return on assets of SD Biosensor Inc is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SD Biosensor Inc (137310)?
The operating margin of SD Biosensor Inc is −7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SD Biosensor Inc (137310)?
Revenue at SD Biosensor Inc is growing +4.4% versus a year earlier (3y avg −37.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SD Biosensor Inc (137310)?
Earnings per share at SD Biosensor Inc are growing +68.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does SD Biosensor Inc (137310) carry?
The net debt of SD Biosensor Inc is 285B KRW (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SD Biosensor Inc in the live analysis
One click puts SD Biosensor Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
